ALK and large cell neuroendocrine carcinoma: Although ALK rearrangement is uncommon in LCNEC, given the patients with ALK rearrangement-positive LCNEC may obtain increased benefit from ALK inhibitors than conventional chemotherapies, clinicians should routinely test for ALK rearrangements in patients with LCNEC, especially in young patients.